Literature DB >> 11566606

The ErbB receptor tyrosine family as signal integrators.

N E Hynes1, K Horsch, M A Olayioye, A Badache.   

Abstract

ErbB receptor tyrosine kinases (RTKs) and their ligands have important roles in normal development and in human cancer. Among the ErbB receptors only ErbB2 has no direct ligand; however, ErbB2 acts as a co-receptor for the other family members, promoting high affinity ligand binding and enhancement of ligand-induced biological responses. These characteristics demonstrate the central role of ErbB2 in the receptor family, which likely explains why it is involved in the development of many human malignancies, including breast cancer. ErbB RTKs also function as signal integrators, cross-regulating different classes of membrane receptors including receptors of the cytokine family. Cross-regulation of ErbB RTKs and cytokines receptors represents another mechanism for controlling and enhancing tumor cell proliferation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11566606     DOI: 10.1677/erc.0.0080151

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  39 in total

1.  Mitogenic signalling in the absence of epidermal growth factor receptor activation in a human glioblastoma cell line.

Authors:  Meng Wang; Patrick Maier; Frederik Wenz; Frank Anton Giordano; Carsten Herskind
Journal:  J Neurooncol       Date:  2013-12       Impact factor: 4.130

2.  SRC-family tyrosine kinases in wound- and ligand-induced epidermal growth factor receptor activation in human corneal epithelial cells.

Authors:  Ke-Ping Xu; Jia Yin; Fu-Shin X Yu
Journal:  Invest Ophthalmol Vis Sci       Date:  2006-07       Impact factor: 4.799

3.  Lysophosphatidic acid promoting corneal epithelial wound healing by transactivation of epidermal growth factor receptor.

Authors:  Ke-Ping Xu; Jia Yin; Fu-Shin X Yu
Journal:  Invest Ophthalmol Vis Sci       Date:  2007-02       Impact factor: 4.799

Review 4.  Transmembrane helix-helix interactions involved in ErbB receptor signaling.

Authors:  Florian Cymer; Dirk Schneider
Journal:  Cell Adh Migr       Date:  2010-04-13       Impact factor: 3.405

5.  Prognostic significance of HER2/neu expression in gastric cancer.

Authors:  Julian Ananiev; Maya Gulubova; Irena Manolova; Georgi Tchernev
Journal:  Wien Klin Wochenschr       Date:  2011-07-11       Impact factor: 1.704

6.  Proteomic screening identifies a YAP-driven signaling network linked to tumor cell proliferation in human schwannomas.

Authors:  Alizée Boin; Anne Couvelard; Christophe Couderc; Isabel Brito; Dan Filipescu; Michel Kalamarides; Pierre Bedossa; Leanne De Koning; Carine Danelsky; Thierry Dubois; Philippe Hupé; Daniel Louvard; Dominique Lallemand
Journal:  Neuro Oncol       Date:  2014-02-20       Impact factor: 12.300

7.  Phase I, dose-finding study of AZD8931, an inhibitor of EGFR (erbB1), HER2 (erbB2) and HER3 (erbB3) signaling, in patients with advanced solid tumors.

Authors:  S Tjulandin; V Moiseyenko; V Semiglazov; G Manikhas; M Learoyd; A Saunders; M Stuart; U Keilholz
Journal:  Invest New Drugs       Date:  2013-04-16       Impact factor: 3.850

Review 8.  Signal integration: a framework for understanding the efficacy of therapeutics targeting the human EGFR family.

Authors:  H Michael Shepard; Cathleen M Brdlik; Hans Schreiber
Journal:  J Clin Invest       Date:  2008-11       Impact factor: 14.808

Review 9.  Decoding epithelial signals: critical role for the epidermal growth factor receptor in controlling intestinal transport function.

Authors:  D F McCole; K E Barrett
Journal:  Acta Physiol (Oxf)       Date:  2008-10-28       Impact factor: 6.311

Review 10.  Promising new molecular targeted therapies in head and neck cancer.

Authors:  Kelly Dorsey; Mark Agulnik
Journal:  Drugs       Date:  2013-03       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.